Citations

Clear

2096 citation(s) found for "Ho, Vincent".

A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement
Lim, Kenneth J C , Greipp, Patricia T. , Kelemen, Katalin, Jevremovic, Dragan, Buadi, Francis K. , Dingli, David, Hayman, Suzanne R. , Kapoor, Prashant , Fonder, Amie , Hobbs, Miriam A, Hwa, Y., Warsame, Rahma , Kourelis, Taxiarchis , Abdallah, Nadine, Zanwar, Saurabh , Lin, Yi, Go, Ronald S., Ailawadhi, Sikander, Cooke, Rachel E. , Zordan, Adrian Carl, Ninkovic, Slavisa , Best, Sharene, Alatorre, Gabriela, Wiedmeier-Nutor, Julia Erin, Einsele, H, Kyle, Robert A, Gertz, MA, Kumar, Shaji , Rajkumar, S Vincent, Fonseca, Rafael, Gonsalves, Wilson I, Yadav, Udit , Rees, Matthew James , Greipp, Patricia T , Dispenzieri, Angela , Baughn, Linda, Buadi, Francis K , Muchtar, E , Leung, Nelson , Fonder, Amie , Hwa, Yi Lisa, Warsame, Rahma , Kourelis, Taxiarchis , Cook, Joselle M , Binder, Moritz , Abdallah, Nadine H , Zanwar, Saurabh S , Siddiqui, Mustaqeem A , Parrondo, Ricardo D , Ailawadi, Sikander, Roy, Vivek , Cooke, Rachel , Best, Sharene H, Alatorre, Gabriela A, Kortüm, Martin , Chhabra, Saurabh , Bergsagel, P. Leif , Gertz, Morie A , Kumar, Shaji K , Fonseca, Rafael , Yadav, Udit , Lim, Kenneth J C , Steinhardt, Maximilian , Rees, Matthew J. , Dispenzieri, Angela , Jevremović, Dragan , Baughn, Linda B. , Dingli, David , Muchtar, Eli , Leung, Nelson , Hobbs, Miriam, Cook, Joselle , Binder, Moritz , Abdallah, Nadine , Go, Ronald S. , Siddiqui, Mustaqeem , Ailawadhi, Sikander , Roy, Vivek , Dun, Karen A. , Zordan, Adrian, Kortüm, K. Martin , Einsele, Hermann , Chhabra, Saurabh , Bergsagel, P. Leif , Kyle, R., Gertz, Morie A. , Rajkumar, S. Vincent , Fonseca, Rafaël , Gonsalves, Wilson I.

Mayo Clinic

Blood Advances | April 22, 2026 | Volume: 10 | Issue: 12 | Pages: 4286-4295

10.1182/bloodadvances.2025019136 | PMID 42018661 Get It

Abstract Solitary bone plasmacytoma (SBP) and SBP with minimal marrow involvement (SBPmm) are treated similarly with definitive radiation therapy (RT) followed by observation. However, differences in the natural disease course after RT between the two, are not well described. We performed a multicenter study assessing outcomes after RT in 141 patients with SBP and 102 with SBPmm diagnosed between January 2010 and December 2024. About 92% of patients with SBPmm progressed to multiple myeloma (MM) vs 76% of those with SBP (P = .01). Among patients with SBP, 21% progressed with a second solitary bone lesion vs 4% with SBPmm (P< .01). Patients with longer time to progression (TTP) after initial RT could achieve durable responses with RT to a second solitary plasmacytoma in the absence of other myeloma-defining events (MDE). Multifocal lytic bone lesions were the most common MDE, occurring in 89% and 81% of patients with SBPmm and SBP, respectively. Patients with SBPmm had a median TTP of 15 months (95% confidence interval [CI], 14-21) compared to 43 months (95% CI, 34-55) for those with SBP (P< .0001); 67% with SBPmm progressed within 2 years of diagnosis. Del(17p) and 1q+ (gain or amplification) were associated with shorter TTP to MM in SBPmm, with 2-year progression rates of 100% and 82%, respectively. We report significant differences in risk and modes of progression between SBP and SBPmm. Patients with SBPmm are at particularly high risk for early progression to MM, with most developing bone disease as the MDE. These findings support prospective studies incorporating frontline systemic therapy for SBPmm.
World Health Organization classification of tumours of the breast 6th edition 2026
Quinn, Cecily , Tan, Puay Hoon , Allison, Kimberly H. , Brogi, Edi , Lakhani, Sunil R. , Schnitt, Stuart J. , Fox, Stephen B. , Jaffer, Shabnam , Şahin, Ayşegül A. , Salgado, Roberto , Adjei, E, Helbich, Thomas H. , Sotiriou, C, Hodge, Jennelle C. , Khoury, Joseph D. , Puspanathan, Pavitratha, Giesen, Christine, Ruiz, Blanca Iciar Indave , Ellis, Ian, Lokuhetty, Dilani , Board, WCT Standing Editorial, Netto, George J. , Sahin, Aysegul , Sapino, Anna , Adjei, Ernest Kwasi , Geiersbach, Katherine , Helbich, Thomas H , Lambertini, Matteo , Sotiriou, Christos P. , Hodge, Jennelle C , Khoury, Joseph , Rekhi, Bharat , Ryska, Ales , Tse, Gary , Field, Andrew , Wijesinghe, Harshima , Puspanathan, Pavitratha , Giesen, Christine , Ruiz, Blanca Iciar Indave , Ellis, Ian , Lokuhetty, Dilani , Geiersbach, Katherine B. , Lambertini, Matteo , Field, Andrew , Ellis, Ian O. , board, WCT standing editorial

Mayo Clinic

Histopathology | April 21, 2026 | Volume: 89 | Issue: 2 | Pages: 199-218

10.1111/his.70149 | PMID 42011085 Get It

The 6th edition of the WHO Classification of Breast Tumours introduces both major and minor changes based on recent advances in our understanding of breast biology, developments in diagnostic modalities, identification of specific molecular targets and new treatment regimens necessitating modifications to pathology reporting and tumour biomarker categorisation. This review summarises the main changes that strive towards a classification of global relevance. In invasive carcinoma, predictive factors increasingly inform modern breast cancer treatment. The 6th edition provides an update on HER2 reporting categories following the DESTINY‐Breast 04 and 06 trials. Terminologies used to classify invasive tumours are clarified, with the term ‘variant’ now reserved for molecular/genetic alterations. Invasive lobular carcinoma (ILC) with extracellular mucin is recognised as a new diagnostic entity with prognostic implications. The diagnosis of mucinous carcinoma (MC) is reserved for mucin secreting carcinomas with grade 1 or 2 morphology and a favourable biomarker profile. The diagnosis of malignant phyllodes tumours requires only four of the original five adverse histological criteria. Classification of neuroendocrine tumours (NETs) is revised, recognising that the unified model, promoted in the 5th edition, is difficult to apply to the breast. New approaches to the classification of adenomyoepithelioma are discussed but the 5th edition system is broadly retained. A new section on ‘Small Diagnostic Samples’ outlines the merits of non‐operative biopsy diagnosis, the B coding system and the importance of multidisciplinary review. Changes to diagnostic practice and the emerging role of artificial intelligence, with advantages and challenges, are discussed in a new section on ‘Digital Pathology’.
Diagnostic utility of immunofixation and free light chain assay in AL amyloidosis: a systematic review and meta-analysis
Azzam, Muayad , Hamarsha, Qais , Kawtharany, Hassan , Nazzal, Jamil, Alkhader, Aseel, Khraise, Tala, AlMasri, Mohammad M., Zeid, Hadi K. Abou, Alwan, Iktimal, Jaber, Nour, Seftel, Matthew D. , Aguirre, M A, Boedicker, Deborah , Bumma, Naresh , Comenzo, Raymond, Dasgupta, Noel R, Torre, Alfredo De La, Jamal, Faizi , Khouri, Jack , Raza, Shahzad, Sarswat, Nitasha , Shaikh, Hira , Singh, Daulath , Kukreti, Vishal, Zeid, Hadi Khaled Abou , Aguirre, María Adela , Abou Zeid, Hadi Khaled , Aguirre, Maria Adela , Carroll, Antonia S , Cook, Joselle M , Dispenzieri, Angela , Jamal, Faizi , Khouri, Jack , Picken, Maria M. , Leung, Nelson , Sanchorawala, Vaishali , Sarswat, Nitasha , Mustafa, Reem A , Kawtharany, Hassan , Shaikh, Hira , Carroll, Antonia , Comenzo, Raymond L. , Cook, Joselle , Dispenzieri, Angela , Raza, Shahzad, Leung, Nelson , Kukreti, Vishal

Mayo Clinic

Blood Advances | April 14, 2026 | Volume: 10 | Issue: 15 | Pages: 5293-5307

10.1182/bloodadvances.2025019530 | PMID 41979328 Get It

Abstract In this systematic review, we aimed to assess the sensitivity of serum immunofixation (SIFE), urine immunofixation (UIFE), and serum free light chain (sFLC) in detecting plasma cell dyscrasia associated with light chain (AL) amyloidosis. We searched the literature using PubMed, Embase, and CENTRAL databases since inception through March 2024. We included studies reporting the diagnostic accuracy of immunofixation and/or sFLC in patients with AL amyloidosis. We used the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach to assess the certainty of the evidence and QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies-2) to assess the risk of bias. After deduplication, 29 237 records were screened, and 44 studies (n = 18 071) were included. For the meta-analysis, 28 studies reported sensitivity for SIFE (n = 3390), 24 studies for UIFE (n = 2830), 19 studies for SIFE and UIFE (n = 2819), 21 studies for sFLC ratio (n = 3678), 6 studies for SIFE and sFLC ratio (n = 372), 3 studies for UIFE and sFLC ratio (n = 242), and 10 studies for all 3 tests (n = 1430). Pooled sensitivities were as follows: SIFE, 0.68 (95% confidence interval [CI], 0.62-0.73); UIFE, 0.77 (95% CI, 0.72-0.81); SIFE and UIFE, 0.89 (95% CI, 0.84-0.93); and sFLC ratio, 0.82 (95% CI, 0.78-0.86). When SIFE, UIFE, and sFLC ratio were combined, the sensitivity reached 0.99 (95% CI, 0.96-1.00). The high sensitivity of combining SIFE, UIFE, and sFLC ratio supports their use as a reliable initial testing strategy to raise suspicion for AL amyloidosis and guide decisions regarding future diagnostic modalities.
Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses
Flerlage, Jamie E. , Eichenauer, Dennis A. , Fuchs, Michael, Hartmann, Sylvia , Eich, Hans Theodor, Savage, Kerry J. , Skinnider, Brian, Akhtar, Saad , Steiner, R., Milgrom, Sarah A., Vega, Francisco, Alomari, Mohammed , Zhang, Xiaoyin , Collins, Graham P., Advani, Ranjana H, Kumar, Priyadarshini , Wirth, Andrew, Tsang, Richard, Smith, SD, Hendrickson, Peter G. , Hopkins, David, McKay, Pamela, Ng, Andrea K. , Koenig, Julie L. , Sakthivel, Gukan, Baron, Jonathan A, Roberts, Kenneth B. , Gao, Sarah, Alkendi, Jalila , Rahbi, Nasser Al, Balogh, Alexander George, Ricardi, Umberto, Sridhar, Akshay, Torka, Pallawi , Specht, Lena , Silva, Ravi De , Shah, Nimish, Osborne, Wendy , Henry, Michael, Chang, Isabela , Halperin, Daniel, Miall, Fiona , Brady, J.L. , Mikhaeel, G., Brennan, Bernadette , Penn, Anthony, Reeves, Marie, Terezakis, Stephanie A, Pepa, R Della, Picardi, Marco, Kirova, Youlia, Fergusson, Paige, Hawkes, Eliza A. , Lee, Denise , Ku, Matthew , Hamad, Nada, Mutsando, Howard , Tedjaseputra, Aditya , Gilbertson, Michael, Marconi, Tamara , Viiala, Nicholas , Palese, Monica , Kelly, Kara M, Borchmann, P, Hoppe, Richard T. , Advani, Ranjana H. , Hopkins, David , Baron, Jonathan , Vega, Francisco , Kumar, Priyadarshini , Dickinson, Michael , Smith, Sonali M , McKay, Pamela , Koenig, Julie , Casulo, Carla , Al Kendi, Jalila , Levis, Mario , Torka, Pallawi , Specht, Lena , De Silva, Ravindu , Pickard, Keir , Smith, Christine M , Brady, Jessica , Senchenko, Maria Anatolevna , Volchkov, Egor Vasilevich , Hoppe, Bradford S , Hawkes, Eliza , Lee, Denise , Doo, Nicole Wong , Barraclough, Allison , Cheah, Chan Yoon , Salvaris, Ross , Ku, Matthew , Hamad, Nada , Tedjaseputra, Aditya , Shankar, Ananth , Maurer, Matthew , Natkunam, Yasodha , Hoppe, Richard T , Binkley, Michael Sargent , Savage, Kerry J , Advani, Ranjana H , Hopkins, David , Baron, Jonathan , Eichenauer, Dennis A , Flerlage, Jamie E , Fuchs, Michael, Eich, Hans Theodor, Hodgson, David C. , Skinnider, Brian, Rauf, M. Shahzad , Maghfoor, Irfan , Pinnix, Chelsea C. , Alomari, Mohammed, Collins, Graham P. , Dickinson, Michael , Tsang, Richard , Prica, Anca A. , Major, Ajay , Kelsey, Chris R. , Constine, Louis S , Casulo, Carla , Plastaras, John Peter , Balogh, Alexander G., Levis, Mario , Ricardi, Umberto , Sridhar, Akshay, Shah, Nimish , Pickard, Keir , Blazin, Lindsay , Henry, Michael, Smith, Christine M. , Hoppe, Bradford S. , Talaulikar, Dipti , Pepa, Roberta Della , Picardi, Marco , Kirova, Youlia , Northend, Michael , Doo, Nicole Wong , Barraclough, Allison , Opat, Stephen , Cheah, Chan Y. , Hamad, Nada , Gilbertson, Michael , Maurer, Matthew J. , Natkunam, Yasodha , Kelly, Kara M. , Borchmann, Peter , Binkley, Michael S.

Mayo Clinic

Blood Advances | April 14, 2026 | Volume: 10 | Issue: 15 | Pages: 5338-5347

10.1182/bloodadvances.2026020012 | PMID 41979337 Get It

Abstract We evaluated outcomes by management type for patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in the Global NLPHL One Working Group retrospective database of 2243 patients with stages I to IV disease diagnosed from 1992 to 2021 at 38 international institutions. A total of 779 patients had stage IA disease with median age of 35 years (range, 3-89) and median follow-up of 6.1 years. The 6-year progression-free survival (PFS) and overall survival were 86.3% and 97.7%, respectively. Outcomes were analyzed for the 2 groups: complete resection and unresected disease. Patients with a complete resection and observation alone (n = 99) had a 6-year PFS of 65.5% vs 90.5% for those who received radiotherapy (RT) (n = 53). Patients with unresected disease (n = 627; 80.5%) had a 6-year PFS of 62.0% for rituximab alone (n = 31), 89.6% for RT alone (n = 325), 76.8% for ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) alone (n = 40), and 94.3% for ABVD plus RT (n = 130). A total of 127 patients relapsed (16.3%), of which 25 (19.7%) had transformation. Our analysis suggests the following: (1) RT improves the PFS in patients with completely resected disease; (2) rituximab or ABVD alone does not appear to achieve a durable response; and (3) chemotherapy was not observed to add additional PFS benefit when used in combination with RT. Thus, for stage IA NLPHL, RT alone is likely sufficient for definitive treatment.
Review of the first on-body injector (OBI) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma
Ocio, E. M., Parmar, Gurdeep , Mateos, María-Victoria, Leleu, Xavier, Buck, Tondre T., Tan, Carlyn Rose, Curry, Nicole C., Quach, Hang, K, E, Bobin, Arthur, Mohty, Mohamad, Ailawadhi, Sikander, Ocio, Enrique M. , Ocio, Enrique M , Mateos, María‐Victoria , Leleu, Xavier , Buck, Tondre, Curry, Nicole C., Ling, Silvia , Quach, Hang , Elias, K. , Bobin, Arthur , Mohty, Mohamad , Ailawadhi, Sikander , Moreau, Philippe

Mayo Clinic

Expert Opinion on Drug Delivery | April 13, 2026 | Volume: 23 | Issue: 7 | Pages: 1289-1303

10.1080/17425247.2026.2659263 | PMID 41973697 Get It

Diabetes as a significant risk factor for postoperative dysphagia following cervical spine surgery
Milne, Catherine, Tippins, Nicholas P., Foreit, Anne M., Alentado, Vincent J. , Bisson, Erica F. , Porche, Ken, Foley, Kevin T, Potts, Eric A. , Milne, Catherine M., Porche, Ken, Foley, Kevin T.

Mayo Clinic

Journal of Neurosurgery: Spine | April 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-11

10.3171/2025.11.spine25838 | PMID 41962152 Get It

OBJECTIVE This study investigated the relationship between diabetes and the incidence of postoperative dysphagia following cervical spine surgery (CSS). METHODS A prospectively collected multi-institutional quality registry was retrospectively reviewed. Patients who underwent CSS were categorized on the basis of diabetes status, and correlations with preoperative and postoperative Eating Assessment Tool-10 (EAT-10) dysphagia questionnaire scores were assessed. Mixed-effects logistic regressions were performed to examine the impact of preoperative diabetes on postoperative dysphagia. RESULTS Of the 2001 patients who met the inclusion criteria, 400 (20%) had diabetes. Baseline dysphagia rates were not significantly different between groups (18% vs 14%, p = 0.08). Patients with diabetes had a significantly higher incidence of dysphagia at 1 month (66% vs 54%, p = 0.002), 3 months (39% vs 26%, p < 0.001), and 12 months (33% vs 24%, p = 0.004) after surgery compared to patients without diabetes. Including baseline dysphagia as a fixed effect, multivariable analysis indicated that diabetes was a significant predictor of postoperative dysphagia at 1 month (OR 1.46, p = 0.041) and 3 months (OR 1.63, p = 0.001) but not at 12 months (OR 1.21, p = 0.3). In patients with no baseline dysphagia, those with diabetes (329 of 400 [82.3%]) had a significantly higher incidence of new dysphagia than nondiabetics at 1 month (62% vs 50%, p = 0.003), 3 months (34% vs 21%, p < 0.001), and 12 months (27% vs 18%, p = 0.001). The mean change in EAT-10 scores between baseline and 12 months was significantly worse in patients with preoperative diabetes (2.440 ± 5.013 vs 1.688 ± 4.139, p = 0.025). Multivariable analysis indicated that diabetes was a significant predictor of new postoperative dysphagia at 1 month (OR 1.49, p = 0.040) and 3 months (OR 1.81, p < 0.001) but not at 12 months (OR 1.31, p = 0.2). CONCLUSIONS Diabetes is a significant risk factor for experiencing postoperative dysphagia following CSS. Diabetes correlated with higher incidence of dysphagia at all postoperative time points and was a strong independent predictor of postoperative dysphagia at 1 and 3 months.
Determinants of gastrointestinal disease burden and survival in systemic AL amyloidosis
Steinhardt, Maximilian , Muchtar, Eli , Kourelis, Taxiarchis , Warsame, Rahma , Mauermann, Michelle Lynn, Buadi, Francis K. , Dingli, David, Leung, Nelson , Cook, Joselle , Go, Ronald S., Hayman, Suzanne R. , Gonsalves, Wilson I, Kapoor, Prashant , Zanwar, Saurabh , Hellou, Tamer , Tan, Melinda S.Y., Halawi, Houssam, Fonder, A C, Hobbs, Miriam, Abdallah, Nadine , Lin, Y., Siddiqui, Mustaqeem, Kyle, R., Einsele, Hermann, Rajkumar, S Vincent, Kumar, Shaji , Steinhardt, Maximilian , Binder, Moritz , Hellou, Tamer , Fonder, Amie , Abdallah, Nadine H , Siddiqui, Mustaqeem A , Kortüm, Martin , Kumar, Shaji K , Gertz, Morie A , Dispenzieri, Angela , Leung, Nelson , Muchtar, E , Buadi, Francis K , Cook, Joselle M , Mauermann, Michelle L. , Dingli, David , Go, Ronald S. , Gonsalves, Wilson I. , Binder, Moritz , Halawi, Houssam , Siddiqui, Mustaqeem , Kortüm, K. Martin , Einsele, Hermann , Rajkumar, S. Vincent , Gertz, Morie A. , Dispenzieri, Angela

Mayo Clinic

Blood Advances | April 9, 2026 | Volume: 10 | Issue: 11 | Pages: 4009-4019

10.1182/bloodadvances.2026019722 | PMID 41954624 Get It

Abstract Gastrointestinal (GI) involvement is a clinically relevant but undercharacterized manifestation of systemic light chain amyloidosis (AL). We aimed to define the clinical spectrum, histologic patterns, and outcomes of symptomatic GI involvement in AL. We retrospectively analyzed 4396 patients with AL from 2010 to 2024, of whom 521 (11.9%) had provider-attributed symptomatic GI involvement; 66% had biopsy-proven GI AL. Symptoms most commonly included early satiety (61%), bowel irregularities (58%), nausea (35%), abdominal pain (28%), and dysphagia (23%). Autonomic neuropathy was frequent (43% clinician attributed; 23% via autonomic reflex testing) and contributed to dysmotility-related symptoms, often without GI biopsy positivity. Among 747 GI biopsies, mucosal infiltration predominated (71%) and was associated with bleeding (22% vs 9%), cachexia, and inferior survival, whereas vascular involvement was associated with lower bleeding risk. Combined involvement of mucosa, submucosa, and vessels conferred the worst prognosis (median overall survival [mOS], 2.4 vs 5.1 vs 7.8 years for 3 vs 2 vs 1 layer); mOS was 6.8 years and was primarily driven by cardiac stage and hematologic response (very good partial response [VGPR] or better: hazard ratio, 0.20; 95% CI 0.13-0.32), with more favorable outcomes in patients with isolated GI involvement. Cachexia and persistent diarrhea were the main drivers of morbidity, need for nutritional support, and GI-related mortality (odds ratio, 2.7 for the combined end point). GI bleeding rarely recurred after achieving VGPR or better. Overall, mucosal involvement, cachexia, and dysmotility define clinically meaningful GI AL and support systematic assessment of autonomic dysfunction as well as evaluation of the need for nutritional support as a GI-specific end point for AL trials.
Micro- and Nanoplastics Exposure and Effects on Embryonic Development and Larval Behavior of Zebrafish
Savage, Kaila S., Harris, Tiara Fryer, Itomura, Luke, Liang, Corina, Mak, Keala, Oglesby, Zachary, Ooi, Vincent, Quiroz, Gemma, Withy, Kelley , Pierret, Chris , Shams, Soaleha , Ooi, Vincent

Mayo Clinic

Zebrafish | April 9, 2026 | Volume: 23 | Issue: 2-3 | Pages: 53-63

10.1177/15458547261441746 | PMID 41951562 Get It

Hawai‘i and other island communities around the globe are experiencing high exposures to micro- and nanoplastics (MNPs). Widespread use of various types of plastics and the action of wave physics coupled with abundant silica creates a constant production of MNPs. The community health effects of exposure to MNPs are not yet fully understood. The aquatic vertebrate model zebrafish, Danio rerio , was utilized to evaluate the developmental and behavioral effects of nanoplastic (NP) exposure as well as visual confirmation of plastic accumulation after embryonic and larval exposure. Eye and yolk size, heart rate, angle of development, and early larval locomotion behavior were quantified after early NP exposure lasting 3 or 5 days. In this work, a digital laboratory environment is used as the context for research trainees spanning high school to graduate and medical school in Hawai‘i to explore health outcomes of developmental NP exposures. Presence of MNPs in the early developmental environment led to changes in growth and behavior of exposed fish. Data analysis showed significant effects of exposures on changes in the rate of development and yolk consumption on day 2 and reduced body length and increased locomotion on day 6. Nanoplastic exposure also affected overall body length, but this effect was not significant. These data support the potential dangers of MNP exposure and demonstrate their persistent detrimental effects on development and behavior in young zebrafish. Accordingly, our work contributes toward shifting focus toward understanding longer impacts on health, growth, and behaviors and potentially the reduction of harm in developing vertebrates.
Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure
Steinhardt, Maximilian , Muchtar, Eli , Kourelis, Taxiarchis , Warsame, Rahma, Buadi, Francis K. , Dingli, D., Leung, Nelson , Cook, Joselle , Go, Ronald S. , HAYMAN, Suzanne, Kapoor, Prashant , Zanwar, Saurabh , Hellou, Tamer , Fonder, Amie , Hobbs, Miriam, Abdallah, Nadine , Lin, Y., Siddiqui, Mustaqeem, Kyle, R., Kortüm, Martin K., Kumar, Shaji , Dingli, David , Dispenzieri, Angela , Steinhardt, Maximilian , Muchtar, E , Kourelis, Taxiarchis , Buadi, Francis K , Dingli, David , Leung, Nelson , Cook, Joselle M , Go, Ronald S , Gonsalves, Wilson , Kapoor, Prashant , Zanwar, Saurabh S , Binder, Moritz , Hellou, Tamer , Abdallah, Nadine H , Lin, Yi , Siddiqui, Mustaqeem A , Kortüm, Martin , Einsele, Hermann , Rajkumar, S Vincent , Kumar, Shaji K , Gertz, Morie A , Dispenzieri, Angela , Warsame, Rahma , Hayman, Suzanne R. , Gonsalves, Wilson I. , Binder, Moritz , Siddiqui, Mustaqeem , Kortüm, K. Martin , Rajkumar, S. Vincent , Gertz, Morie A.

Mayo Clinic

No container title available | April 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9227260/v1 | PMID 41994108 Get It

Abstract Systemic light chain amyloidosis (AL) arises from monoclonal immunoglobulin light chains, but determinants of progression from precursor states remain poorly defined. In a cross-sectional cohort comprising 1950 systemic AL patients diagnosed 2010-2024, 258 (13.2%) patients with a previously diagnosed plasma cell disorder (PCD) were compared to patients with no prior PCD diagnosis. Patients with monoclonal gammopathy of undetermined signficance (MGUS) and smoldering multiple myeloma (SMM) in the former group had lower difference between involved and uninvolved FLCs (dFLC), higher M-protein, and lower rates of t(11;14) at AL diagnosis. Patients developing AL from SMM had a shorter time to AL (median 34.2 versus 61.3 months) and higher dFLC (median 28.9 versus 11.0 mg/dl) compared to those from MGUS. Patients developing AL after known multiple myeloma (MM) or lymphoplasmacytic lymphoma (LPL) commonly lacked deep hematologic response before AL (≤ very good partial response in 78% of MM, 100% of LPL patients). We additionally studied longitudinally followed cohorts of 3,966 MGUS and 426 (SMM) patients with longitudinal FLC measurements and matched follow-up, in which 1.8% of MGUS and 7.2% of SMM patients developed AL. Those patients who developed AL showed markedly higher dFLC at MGUS/SMM diagnosis and more frequent λ restriction and rates of t(11;14). Higher dFLC was associated with progressively earlier AL development; a 10% cumulative risk occurred at 20 months for patients with a dFLC >80 mg/dL but was not reached if dFLC <10 mg/dL at an estimated median follow-up of 86 months. In multivariable analysis, dFLC >6.4 mg/dL (HR 11.3) and λ isotype (HR 3.6) independently predicted AL, whereas heavy chain secretion was associated with lower risk (HR 0.2 for IgG). These findings indicate that AL risk is primarily driven by cumulative light chain exposure, refining our knowledge of AL pathophysiology and providing guidance for follow-up of patients with elevated dFLC.
Retreatment with First-Generation Selective RET Inhibitors in RET -Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry
Marinello, A., Rotow, Julia K., Lomibao, Meghanne , Miliziano, Daniela , Leporati, Rita , Feng, Jamie , Metro, Giulio , Brandão, Mariana , Gorría, Teresa , Nassar, Amin H. , Fila, Matteo, Fallet, V., Ricciuti, Biagio, Taylor, Skyler, Remon, Jordi, Planchard, David, Florez, Narjust, Besse, Benjamin, Drilon, Alexander D., Aldea, Mihaela, Nassar, Amin H. , Rotow, Julia , Metro, Giulio , Marinello, Arianna , Marinello, Arianna , Rotow, Julia K. , Citarella, Fabrizio , Fila, Matteo , Fallet, Vincent , Ricciuti, Biagio , Taylor, Skyler , Remon, Jordi , Planchard, David , Duma, Narjust , Besse, Benjamin , Drilon, Alexander , Aldea, Mihaela , Feng, Jamie , Citarella, Fabrizio , Ricciuti, Biagio , Planchard, David , Florez, Narjust , Besse, Benjamin , Aldea, Mihaela

Mayo Clinic

Clinical Cancer Research | April 7, 2026 | Volume: 32 | Issue: 13 | Pages: 2637-2643

10.1158/1078-0432.ccr-25-4814 | PMID 41945500 Get It

Abstract Purpose: In RET-rearranged non–small cell lung cancer (NSCLC), treatment options after first-generation selective RET inhibitors (SRI) are limited, and the value of SRI retreatment remains unclear. This study evaluates outcomes of SRI retreatment. Experimental Design: This multicenter retrospective study included patients with advanced RET-rearranged NSCLC who received ≥2 SRI-based therapy lines. Of 411 SRI-treated patients, 41 (10%) underwent SRI retreatment. Outcomes included objective response rate (ORR), progression-free survival (PFS), 6-month PFS, time to treatment failure, adverse events (AE). Results: Among 41 patients, 14 (34%) discontinued the initial SRI because of toxicity and 27 (66%) because of progression. After discontinuation for toxicity, all switched to an alternate SRI, achieving an ORR of 67%, median PFS of 9.9 months, and 6-month PFS of 80.3%. AEs reoccurred in nine patients (64%), with grade ≥3 AEs in 3 (21%) who switched at full dose. Among patients who discontinued because of progression, SRI monotherapy (n = 13) achieved an ORR of 23%, median PFS of 7 months, and 6-month PFS of 61.5%. Benefit was observed in patients with brain-only or oligoprogressive disease or dose reduction on first SRI. Combination therapy (n = 14; targeted agents, n = 11; chemotherapy, n = 3) achieved an ORR of 39%, median PFS of 4 months, and 6-month PFS of 27.3%. Conclusions: Same-class SRI switch after toxicity is feasible and clinically active but warrants cautious, dose-adjusted switching to mitigate toxicities. The efficacy of SRI rechallenge after progression seems limited overall. However, selected patients, such as those with brain-only or oligoprogressive disease, may derive benefit.